Skip to main content

Table 2 List of identified beneficial overlapping peptides (OLP, PR > 1) incorporated in the final T-cell immunogen design, based on previous analysis [28]

From: A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

OLP no. Protein Subunit OLP clade B cons sequence
3 Gag p17 EKIRLRPGGKKKYKLKHI
6 Gag p17 ASRELERFAVNPGLL
7 Gag p17 ERFAVNPGLLETSEGCR
10 Gag p17 QLQPSLQTGSEELRSLY
12 Gag p17 SLYNTVATLYCVHQRIEV
23 Gag p24 AFSPEVIPMFSALSEGA
31 Gag p24 IAPGQMREPRGSDIA
34 Gag p24 STLQEQIGWMTNNPPIPV
48 Gag p24 ACQGVGGPGHKARVLAEA
60 Gag p15 GKIWPSHKGRPGNFLQSR
75 Nef - WLEAQEEEEVGFPVRPQV
159 Pol Prt KMIGGIGGFIKVRQYDQI
160 Pol Prt FIKVRQYDQILIEICGHK
161 Pol Prt QILIEICGHKAIGTVLV
163 Pol Prt LVGPTPVNIIGRNLLTQI
171 Pol RT LVEICTEMEKEGKISKI
195 Pol RT LRWGFTTPDKKHQKEPPF
196 Pol RT DKKHQKEPPFLWMGYELH
210 Pol RT EIQKQGQGQWTYQIY
269 Pol Int TKELQKQITKIQNFRVYY
270 Pol Int TKIQNFRVYYRDSRDPLW
271 Pol Int YYRDSRDPLWKGPAKLLW
276 Pol Int KIIRDYGKQMAGDDCVA
405 Vif - VKHHMYISGKAKGWFYRH
406 Vif - GKAKGWFYRHHYESTHPR
424 Vif - TKLTEDRWNKPQKTKGHR